Company Intelligence

Menten AI

Menten AI designs protein drugs and enzymes using quantum computing and machine learning. Their technology leapfrogs current computational methods making it possible to design previously intractable proteins. The team created the first protein design algorithm for…

In this profile

Quick Facts

  • Founded 2020
  • Headquarters San Francisco, United States
  • Country United States
  • Industry AI in Healthcare
  • Company Type Early
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

Menten AI designs protein drugs and enzymes using quantum computing and machine learning. Their technology leapfrogs current computational methods making it possible to design previously intractable proteins. The team created the first protein design algorithm for current and near-term quantum computers and created the world’s first protein designed on a quantum computer. They are now working on 3 new proteins, including a peptide to prevent the spread of viruses like Covid-19. They have 2 paid pilot projects with multinational chemical companies and 4 LOI’s with pharma and biotech companies.

Why It Matters

Menten AI designs peptide and protein therapeutics using quantum…

Recent Developments

  1. 2020 Company founded

    Menten AI was founded in 2020 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

Menten AI designs protein drugs and enzymes using quantum computing and machine learning. Their technology leapfrogs current computational methods making it possible to design previously intractable proteins. The team created the first protein design algorithm for current and near-term quantum computers and created the world’s first protein designed on a quantum computer. They are now working on 3 new proteins, including a peptide to prevent the spread of viruses like Covid-19. They have 2 paid pilot projects with multinational chemical companies and 4 LOI’s with pharma and biotech companies.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe